Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Genmab A (GNMSF) Long-Term Investments (2023 - 2025)

Historic Long-Term Investments for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $37.0 million.

  • Genmab A's Long-Term Investments rose 1562.5% to $37.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $37.0 million, marking a year-over-year increase of 1562.5%. This contributed to the annual value of $37.0 million for FY2025, which is 1562.5% up from last year.
  • Genmab A's Long-Term Investments amounted to $37.0 million in Q4 2025, which was up 1562.5% from $36.0 million recorded in Q3 2025.
  • Genmab A's Long-Term Investments' 5-year high stood at $37.0 million during Q4 2025, with a 5-year trough of $20.0 million in Q4 2023.
  • Its 3-year average for Long-Term Investments is $31.7 million, with a median of $33.5 million in 2024.
  • Its Long-Term Investments has fluctuated over the past 5 years, first soared by 6000.0% in 2024, then surged by 1562.5% in 2025.
  • Quarter analysis of 3 years shows Genmab A's Long-Term Investments stood at $20.0 million in 2023, then skyrocketed by 60.0% to $32.0 million in 2024, then rose by 15.62% to $37.0 million in 2025.
  • Its Long-Term Investments stands at $37.0 million for Q4 2025, versus $36.0 million for Q3 2025 and $35.0 million for Q2 2025.